1. HOME
2. Research Insight
3. Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), and GE Healthcare (US) were the Leading Players in the Cell Culture Market

The cell culture market is projected to reach USD 33.1 billion by 2025 from USD 19.0 billion in 2020, at a CAGR of 11.8% during the forecast period. The growing awareness about the benefits of cell culture-based vaccines, increasing demand for monoclonal antibodies, increasing demand for personalized medicine, increasing pharmaceutical and biotechnology R&D expenditure and government funding for cell-based research, growing preference for single-use technologies, and increasing focus on personalized medicine are the primary growth factors for this market. Also, growing demand for 3D cell culture, the growing risk of pandemics and communicable diseases, and emerging economies are expected to offer significant opportunities for market growth in the coming years. However, the high cost of cell biology research and the lack of proper infrastructure for cell-based research activities is expected to restrain market growth to a certain extent.

The cell culture market is consolidated at the top with a large number of leading market players based in developed countries. The prominent players operating in this market include Thermo Fisher Scientific (US), Merck KGaA (Germany), GE Healthcare (US), Danaher Corporation (US), Lonza Group AG (Switzerland), Becton, Dickinson and Company (US), Corning Incorporated (US), Eppendorf (Germany), HiMedia Laboratories (India), Sartorius AG (Germany), PromoCell GmbH (Germany), FUJIFILM Irvine Scientific (US), InvivoGen (US), CellGenix GmbH (Germany), SeraCare Life Sciences Incorporation (US), Miltenyi Biotec (Germany), STEMCELL Technologies, Inc. (Canada), Solida Biotech GmBH (Germany), Caisson Labs Inc. (US), Cellexus Ltd, (UK), PIERRE GUÉRIN (France), Applikon Biotechnology BV (Netherlands), WISENT Inc. (Canada), Koh Jin-Bio Co., Ltd. (Japan), PAN-Biotech GmbH (Germany), and Infors AG (Switzerland).  However, in the last few years, a number of smaller players have emerged from niche markets, and are competing with global players based on price and technological innovation. Due to the intense competition in the market, major market players are increasingly focusing on expanding their geographic presence into the high-growth emerging markets and strengthening their technological competitiveness in the market by acquiring smaller players with the desired technological capabilities or geographic presence.

To know about the assumptions considered for the study download the pdf brochure

Thermo Fisher Scientific is one of the leading players in the cell culture market. The leading position of the company can be attributed to its established brands such as Gibco, Nunc, Countess, Mr. Frosty, Dynabeads, and Lipofectamine and the company’s robust product portfolio for cell culture.  To maintain its leading position in the cell culture market, the company adopts organic and inorganic growth strategies such as new product launches, expansions, and acquisitions. In November 2019, Thermo Fisher Scientific invested USD 24 million in its Inchinnan, Scotland, site to expand global bioproduction capabilities with additional large volume liquid manufacturing capacity for cell culture media. The company focuses on investing in R&D activities to launch new and advanced products. For instance, in 2018, the company launched the Cell Locker system, the Cloud-Enabled Biological Safety Cabinet, and its Invitrogen EVOS M7000 microscope. Thermo Fisher’s efforts towards enhancing its product portfolio have significantly helped the company establish its leading position in the cell culture market

Merck KGaA (Germany) was the second-largest player in the cell culture market in 2019. The company has a strong portfolio of cell culture products, including cell culture equipment, cell culture media, reagents, and sera. In order to maintain its strong position in the market, the company focuses on adopting organic as well as inorganic growth strategies such as acquisitions and new product launches. The company’s focus on inorganic growth strategies is evident from its recent (March 2019) collaboration with GenScript (China) to fast-track the commercialization of cell & gene therapy platform by building a global-standard platform for plasmid and virus manufacturing in China. Furthermore, Merck has a well-organized supply chain that delivers standard products in 24 to 48 hours worldwide. The company focuses on new product launches in order to leverage growth opportunities in the cell culture market. Some of its recent launches include CellStream benchtop flow cytometry system (April 2018), Viresolve Barrier capsule filters to reduce the risk of bioreactor contamination (February 2018), EX-CELL Advanced HD Perfusion Medium (May 2017), and Millistak+ HC Pro (September 2017), among others. Such developments help in expanding Merck’s presence in the cell culture market, thus maintaining its leading position.

GE Healthcare (US) was the third-largest player in the cell culture market in 2019. The company has an exhaustive product portfolio, which includes classical media, specialty media, calf sera, FBS, FBS alternatives, specialty sera, other sera, reagents & supplements, balanced salts, and buffers. GE Healthcare focuses on adopting organic and inorganic business strategies. In May 2018, GE Healthcare- Cytiva increased its annual production capacity of powdered cell culture media by tenfold. This development strengthened the product supply for biopharmaceutical companies in Europe. The company also doubled its powdered cell culture media manufacturing capacity in the US. In November 2017, GE Healthcare (US) acquired Puridify (UK). This acquisition helped GE Healthcare to enhance its production of biopharmaceuticals. Such acquisitions help strengthen the company’s product offerings in the cell culture market. GE Healthcare also focuses on strategies such as collaborations and partnerships to enhance and maintain its market position. For instance, in July 2017, GE partnered with Oritain (New Zealand) to launch an independent test-based traceability program to validate the country of origin of the Fetal Bovine Serum (FBS).

However, in April 2020, Danaher acquired the biopharma business segment of GE Healthcare, including its cell culture business. With this acquisition, GE has quit the cell culture market. This acquisition is expected to increase the share of Danaher Corporation in the cell culture market in 2020.

Related Reports:

Cell Culture Market by Product (Consumables (Media, Serum, Vessels), Equipment (Bioreactor, Centrifuge, Incubator, Autoclave)), Application (Therapeutic Proteins, Vaccines, Diagnostics, Stem cells), End User (Pharma, Biotech) - Global Forecast to 2025

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com